Current Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2024 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses.
Journal Article JAMA Oncol · October 1, 2025 IMPORTANCE: Much of the understanding of cancer risk associated with rare pathogenic variants (RPVs) is derived from family-based studies or clinically ascertained samples, which may be limited by ascertainment and selection bias. OBJECTIVE: To quantify as ... Full text Open Access Link to item CiteGenetics of prostate cancer.
Journal Article Clin Adv Hematol Oncol · May 2025 Prostate cancer is a highly heritable cancer, with contributions from rare pathogenic variants in prostate cancer predisposition genes (eg, HOXB13, BRCA2) and from common genetic variants throughout the genome. Only HOXB13 has been identified as a prostate ... Link to item CiteIncorporating Structured and Unstructured Data Sources to Identify and Characterize Hereditary Cancer Testing Among Veterans With Metastatic Castration-Resistant Prostate Cancer.
Journal Article JCO Clin Cancer Inform · February 2025 PURPOSE: This study introduces an integrated approach using structured and unstructured data from an electronic health record to identify and characterize patient utilization of hereditary cancer genetic testing among patients with metastatic castration-re ... Full text Link to item CiteRecent Grants
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2024 - 2029TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in c
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2025 - 2029Kidney Cancer Research Program Clinical Consortium Duke University Clinical Trial Site Award
ResearchCo Investigator · Awarded by Department of Defense · 2024 - 2028View All Grants
Education, Training & Certifications
Icahn School of Medicine at Mount Sinai ·
2017
M.D.